How it works
Technical papers
Patents
Biophotonics
News Room
Click on Images to Download
Guided Therapeutics Selects CAN-med Healthcare to Distribute LuViva® Advanced Cervical Scan in Canada
Guided Therapeutics Submits CE Mark Approval Application for LuViva® Advanced Cervical Scan
Guided Therapeutics Provides Update on PMA Application for LuViva® Advanced Cervical Scan and Timing for Filing of CE Mark
Guided Therapeutics Selects Eurosurgical Ltd to Distribute LuViva™ Advanced Cervical Scan in the United Kingdom
Health Canada Approves Guided Therapeutics' LuViva™ Advanced Cervical Scan for Detecting Precancer of the Cervix
Santé Canada approuve le scanner avancé de l’utérus LuVivaMC de Guided Therapeutics pour le dépistage du précancer du col de l’utérus
National Cancer Institute Designates Guided Therapeutics’ LuViva™ Advanced Cervical Scan an Investment Success Story
Guided Therapeutics Reports Q3 2011 Results
Guided Therapeutics Reports Update on FDA Review of LuViva™ Advanced Cervical Scan PMA Application
Guided Therapeutics to Showcase LuVivaTM Advanced Cervical Scan at Medica 2011
Guided Therapeutics Awarded Third Year Funding of National Cancer Institute Grant for LuViva™ Advanced Cervical Scan
Guided Therapeutics Begins Human Feasibility Clinical Study for Light-based Barrett’s Esophagus Technology Jointly Developed with Konica Minolta Opto
Guided Therapeutics Enters into Preliminary Research Agreement with Konica Minolta Opto in Anticipation of Asian Distribution; Plan to Initiate Screening Trials for LuViva Advanced Cervical ScanGuided Therapeutics Provides Progress Update on its Response to FDA Questions
Guided Therapeutics Reports First Quarter 2011 Results
Study Indicates Guided Therapeutics’ LuViva Advanced Cervical Scan Has Potential to Detect Disease Early and Reduce Unnecessary Biopsies for Women
Guided Therapeutics Introduces LuViva™; New Branding for Cervical Disease Detection Technology
Guided Therapeutics Holds Productive Meeting with FDA on PMA Review of Cervical Cancer Test
Guided Therapeutics Reports Fourth Quarter and Year End 2010 Results
Konica Minolta Opto, Inc. Extends Product Development Licensing Agreement with $750,000 Payment to Guided Therapeutics
Guided Therapeutics Granted Approval for Human Clinical Studies of Light-based Test for Barrett’s Esophagus Pipeline Product
Guided Therapeutics Provides Update on FDA PMA Review of Cervical Cancer Test
Guided Therapeutics’ Cervical Disease Detection Technology to be the Subject of a Presentation at the Upcoming ACOG Annual Meeting
Guided Therapeutics’ Cervical Disease Technology Accepted for Presentation at Major European Scientific Conference
Guided Therapeutics Receives ISO Certification
FDA Accepts Guided Therapeutics’ Non-Invasive Cervical Cancer Scanner PMA Application for Review
Guided Therapeutics Reports Third Quarter 2010 Results
Guided Therapeutics Awarded Federal Grant
Guided Therapeutics Files Premarket Approval Application for Non-Invasive Cervical Cancer Scanner with FDA
Guided Therapeutics Completes $3 Million Financing
National Cancer Institute Funds Second Year of Grant to Guided Therapeutics to Commercialize Non-invasive Cervical Cancer Detection Device
Leading Expert in Women’s Health Elected to Guided Therapeutics Board of Directors
Guided Therapeutics Reports First Quarter 2010 Results... Read More
Guided Therapeutics’ Cervical Scan Could Save Money, Reduce Suffering According to Results Presented at Europe’s Foremost International Congress for OB-GYN... Read More
Konica Minolta Opto, Inc. Extends Product Development Licensing Agreement with Guided Therapeutics... Read More
LightTouch in the news. WSVN News in Miami report... Click to view
Guided Therapeutics LightTouch Cervical Scan FDA Trial Indicates Improved Detection of Significant Disease over Pap in Private Office Setting
Guided Therapeutics LightTouch Cervical Scan FDA Clinical Trial Indicates Adolescent’s Risk for Cervical Disease on Par with Adult Women
Guided Therapeutics’ LightTouch Cervical Scan Detected Disease Up to Two Years Earlier Than Pap, HPV and Biopsy in FDA Pivotal Clinical Trial
Top Doctors to Present Results of FDA Clinical Trial of Guided Therapeutics’ Cervical Cancer Detection Technology at Scientific Meeting
Guided Therapeutics, Inc. Receives New Funding Commitment from Konica Minolta Opto, Inc. to Expand Cancer Detection Product Line
Guided Therapeutics Non-invasive Cervical Cancer Detection Device Trial Confirms Current Tests Miss Disease; Create High False Positive Rates
Guided Therapeutics to Introduce New Cancer Detection Technology at Medica 2009
Guided Therapeutics, Inc. Awarded $2.5 million Grant by National Cancer Institute Guided Therapeutics, Inc. and Konica Minolta Opto, Inc. to Jointly Develop Cancer Detection Products
Guided Therapeutics, Inc. Reports Preliminary Findings from FDA Pivotal Clinical Trial ...Read More
Guided Therapeutics, Inc. Submits First Module of Premarket Approval Application for Painless Cervical Cancer Detection to FDA ...Read More
Guided Therapeutics, Inc. and Konica Minolta Extend Agreement to Expand Cancer Detection Technology ...Read More
Guided Therapeutics, Inc. Announces Completion of Subject Enrollment of FDA Pivotal Clinical Trial
Guided Therapeutics, Inc. Announces the Appointment of Former Delta Air Lines CEO Ronald W. Allen to Board of Directors
Guided Therapeutics, Inc. New Stock Ticker Symbol - GTHP
Guided Therapeutics, Inc. and Konica Minolta Look to Expand Cancer Detection Technology
Agreement Signed to Manufacture New Non-invasive Cancer Detection Devices
New Painless Test for Cervical Cancer Could Provide Access to Better Healthcare for Women Worldwide
Pre-PMA Meetings Held with FDA on Painless Cervical Cancer Test
Painless Cancer Test May Eliminate Half of Unnecessary Cervical Biopsies
Two Clinical Studies Indicate SpectRx (Guided Therapeutics) Non-invasive Cervical Cancer Detection Device Accurately Detects Disease While Reducing False Positive Results
SpectRx, Inc. (Guided Therapeutics) Granted Patent for Non-invasive Cervical Cancer Detection Technology
SpectRx, Inc. (Guided Therapeutics) Successfully Builds and Tests First Pre-production Non-invasive Cervical Cancer Detection Device
SpectRx, Inc. (Guided Therapeutics) Granted Key Patent for Non-invasive Cervical Cancer Detection Technology
Emory and (Guided Therapeutics) SpectRx, Inc. Partner in Georgia Research Alliance Innovation Fund Project for Clinical Trials of Non-invasive Cervical Cancer Detection Device
(Guided Therapeutics) SpectRx, Inc. Selected for an Additional $1.1 Million Grant by National Cancer Institute for Non-invasive Cervical Cancer Detection Technology
(Guided Therapeutics) SpectRx, Inc. Begins Initial Phase of FDA Pivotal Clinical Trial for Non-invasive Cervical Cancer Detection Test
(Guided Therapeutics) SpectRx Completes National Cancer Institute Clinical Trial of Non-invasive Cervical Cancer Test
Published Study Shows 81% of Women Want SpectRx Non-invasive Cervical Cancer Test to Replace Pap Test
©2012 Guided Therapeutics, Inc.
5835 Peachtree Corners East
Suite D
Norcross, GA 30092
770-242-8723
770-242-8639 - Fax
www.guidedinc.com
info@guidedinc.com
Terms of Service
